All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Consultant-Needed-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

JHL Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar

Contact the Supplier

Lead Product(s): Denosumab

Therapeutic Area: Musculoskeletal Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

The Three-Arm Study is randomized, double-blinded, parallel-grouped, and single-dosed and will compare the pharmacokinetic similarity of JHL1266 versus Prolia® sourced from the EU and the US in healthy human subjects.